Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. Watanabe T, et al. Among authors: sano m. J Clin Oncol. 2009 Mar 20;27(9):1368-74. doi: 10.1200/JCO.2008.18.3939. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204202 Clinical Trial.
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial).
Ohashi Y, Watanabe T, Sano M, Koyama H, Inaji H, Suzuki T. Ohashi Y, et al. Among authors: sano m. Breast Cancer Res Treat. 2010 Feb;119(3):633-41. doi: 10.1007/s10549-009-0635-3. Breast Cancer Res Treat. 2010. PMID: 19936917 Clinical Trial.
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208.
Tokuda Y, Tajima T, Narabayashi M, Takeyama K, Watanabe T, Fukutomi T, Chou T, Sano M, Igarashi T, Sasaki Y, Ogura M, Miura S, Okamoto S, Ogita M, Kasai M, Kobayashi T, Fukuda H, Takashima S, Tobinai K; Autologous Bone Marrow Transplantation Study Group; Breast Cancer Study Group of the Japan Clinical Oncology Group (JCOG). Tokuda Y, et al. Among authors: sano m. Cancer Sci. 2008 Jan;99(1):145-51. doi: 10.1111/j.1349-7006.2007.00639.x. Epub 2007 Oct 25. Cancer Sci. 2008. PMID: 17970786 Free PMC article. Clinical Trial.
Long-term results of breast-conserving treatment for early-stage breast cancer in Japanese women from multicenter investigation.
Ohsumi S, Sakamoto G, Takashima S, Koyama H, Shin E, Suemasu K, Nishi T, Nakamura S, Iino Y, Iwase T, Ikeda T, Teramoto S, Fukutomi T, Komaki K, Sano M, Sugiyama K, Miyoshi K, Kamio T, Ogita M. Ohsumi S, et al. Among authors: sano m. Jpn J Clin Oncol. 2003 Feb;33(2):61-7. doi: 10.1093/jjco/hyg014. Jpn J Clin Oncol. 2003. PMID: 12629055
1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial.
Tominaga T, Kimura M, Asaga T, Yoshida M, Awane H, Koyama H, Takatsuka Y, Mitsuyama S, Ikeda T, Ogita M, Aoyama H, Sano M, Abe R, Nishi T, Wada T, Danno M, Toi M, Takashima S. Tominaga T, et al. Among authors: sano m. Oncol Rep. 2004 Oct;12(4):797-803. Oncol Rep. 2004. PMID: 15375502 Clinical Trial.
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, Tokuda Y, Mitsuyama S, Kimura M, Kobayashi T, Tamura M, Tabei T, Shin E, Nishimura R, Ohno S, Takashima S. Toi M, et al. Among authors: sano m. Jpn J Clin Oncol. 2005 Jun;35(6):310-5. doi: 10.1093/jjco/hyi090. Epub 2005 Jun 1. Jpn J Clin Oncol. 2005. PMID: 15930037 Clinical Trial.
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Inoue K, et al. Among authors: sano m. Breast Cancer Res Treat. 2010 Jan;119(1):127-36. doi: 10.1007/s10549-009-0498-7. Epub 2009 Aug 19. Breast Cancer Res Treat. 2010. PMID: 19690954 Clinical Trial.
Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan.
Chou T, Sano M, Ogura M, Morishima Y, Itagaki H, Tokuda Y. Chou T, et al. Among authors: sano m. Breast Cancer. 2005;12(3):178-88. doi: 10.2325/jbcs.12.178. Breast Cancer. 2005. PMID: 16110287 Free article. Clinical Trial.
2,617 results